These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36577220)

  • 21. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Zhang J; Zhan P; Wu J; Li Z; Jiang Y; Ge W; Pannecouque C; De Clercq E; Liu X
    Bioorg Med Chem; 2011 Jul; 19(14):4366-76. PubMed ID: 21683601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors.
    Li W; Huang B; Kang D; De Clercq E; Daelemans D; Pannecouque C; Zhan P; Liu X
    Chem Biol Drug Des; 2016 Sep; 88(3):380-5. PubMed ID: 27062197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Wu HQ; Yao J; He QQ; Chen WX; Chen FE; Pannecouque C; De Clercq E; Daelemans D
    Bioorg Med Chem; 2015 Feb; 23(3):624-31. PubMed ID: 25537532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs.
    Zhou RL; Ju Z; Pannecouque C; Clercq E; Wang S; Chen FE
    Eur J Med Chem; 2023 Jan; 246():114939. PubMed ID: 36442370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors.
    Tramontano E; Marongiu ME; de Montis A; Loi AG; Artico M; Massa S; Mai A; la Colla P
    New Microbiol; 1994 Oct; 17(4):269-79. PubMed ID: 7532270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
    Mai A; Artico M; Rotili D; Tarantino D; Clotet-Codina I; Armand-Ugón M; Ragno R; Simeoni S; Sbardella G; Nawrozkij MB; Samuele A; Maga G; Esté JA
    J Med Chem; 2007 Nov; 50(22):5412-24. PubMed ID: 17910429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Hao QQ; Chen XM; Pannecouque C; De Clercq E; Wang S; Chen FE
    Bioorg Chem; 2023 Apr; 133():106413. PubMed ID: 36791619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
    Feng D; Lin H; Jiang L; Wang Z; Sun Y; Zhou Z; Clercq E; Pannecouque C; Kang D; Zhan P; Liu X
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors.
    Huang Y; Wang X; Yu X; Yuan L; Guo Y; Xu W; Liu T; Liu J; Shao Y; Ma L
    Virol J; 2011 May; 8():230. PubMed ID: 21569631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Sang Y; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Eur J Med Chem; 2019 Nov; 182():111603. PubMed ID: 31421633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
    Mai A; Artico M; Sbardella G; Quartarone S; Massa S; Loi AG; De Montis A; Scintu F; Putzolu M; La Colla P
    J Med Chem; 1997 May; 40(10):1447-54. PubMed ID: 9154967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity.
    D'Cruz OJ; Uckun FM
    Biol Reprod; 1999 Jun; 60(6):1419-28. PubMed ID: 10330101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
    Jin X; Piao HR; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2021 Dec; 226():113868. PubMed ID: 34583311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs.
    Radi M; Falciani C; Contemori L; Petricci E; Maga G; Samuele A; Zanoli S; Terrazas M; Castria M; Togninelli A; Esté JA; Clotet-Codina I; Armand-Ugón M; Botta M
    ChemMedChem; 2008 Apr; 3(4):573-93. PubMed ID: 18081133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
    Mao Y; Li Y; Hao M; Zhang S; Ai C
    J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, biological activity, and ADME properties of novel S-DABOs/N-DABOs as HIV reverse transcriptase inhibitors.
    Radi M; Pagano M; Franchi L; Castagnolo D; Schenone S; Casaluce G; Zamperini C; Dreassi E; Maga G; Samuele A; Gonzalo E; Clotet B; Esté JA; Botta M
    ChemMedChem; 2012 May; 7(5):883-96. PubMed ID: 22419605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-nucleoside HIV reverse transcriptase inhibitors, Part 6[1]: synthesis and anti-HIV activity of novel 2-[(arylcarbonylmethyl)thio]-6-arylthio DABO analogues.
    Sun GF; Kuang YY; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Arch Pharm (Weinheim); 2005 Oct; 338(10):457-61. PubMed ID: 16211654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.